Paper Details

  1. Home
  2. Paper Details

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.

Author: , FeaganBrian G, GerminaroMatthew, JohannsJewel, PanésJulián, SandbornWilliam J, SandsBruce E, ShaoJie, ShengShihong, VetterMarion

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study examines whether combining guselkumab and golimumab is more effective for treating ulcerative colitis than either medication alone. Ulcerative colitis is a chronic inflammatory bowel disease with limited treatment options.
Paper Details　
Original Abstract of the Article :
Despite the introduction of new monoclonal antibodies and oral therapies for the treatment of ulcerative colitis, clinical remission rates remain low, underscoring the need for innovative treatment approaches. We assessed whether guselkumab plus golimumab combination therapy was more effective for u...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S2468-1253(22)00427-7

データ提供：米国国立医学図書館（NLM）

Guselkumab Plus Golimumab: A New Combination Therapy for Ulcerative Colitis

Ulcerative colitis is a complex and challenging disease, like a harsh desert environment that can leave patients feeling lost and uncomfortable. This study investigates the potential benefits of combining two monoclonal antibodies, guselkumab and golimumab, to treat ulcerative colitis. The researchers designed a randomized, double-blind, controlled, phase 2 proof-of-concept trial to compare the efficacy of this combination therapy with monotherapy. The study’s findings suggest that the combination therapy may be more effective than either monotherapy alone in achieving clinical remission.

The Power of Combination Therapy

The study’s results offer a potential breakthrough in the treatment of ulcerative colitis, suggesting that combining guselkumab and golimumab may lead to improved outcomes for patients.

Finding Oasis in the Desert of Ulcerative Colitis

Ulcerative colitis is a challenging disease, like a relentless desert heat that can cause discomfort and pain. This study offers a potential solution, highlighting the potential benefits of combination therapy in finding relief and improving quality of life.

Dr.Camel's Conclusion

This research suggests that combination therapy with guselkumab and golimumab may offer a promising approach to treating ulcerative colitis. This finding provides hope for patients seeking effective treatment options in the vast desert of ulcerative colitis research.

Date :
  1. Date Completed 2023-03-14
  2. Date Revised 2023-04-13
Further Info :

Pubmed ID

36738762

DOI: Digital Object Identifier

10.1016/S2468-1253(22)00427-7

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.